Literature DB >> 14603247

Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.

Harald Löffler1, Randi G Syljuåsen, Jirina Bartkova, Jesper Worm, Jiri Lukas, Jiri Bartek.   

Abstract

The rapid cell cycle arrest in response to DNA damage is mediated by degradation of the Cdc25A phosphatase, a proto-oncogene whose mRNA is frequently overexpressed in human tumours. Here, we study the occurrence and mechanisms of Cdc25A deregulation in human breast cancer cell lines. We demonstrate aberrantly elevated Cdc25A protein abundance and phosphatase activity in eight out of 15 cell lines, in some cases resulting in abrogation of the Cdc25A-mediated checkpoint response to ionizing radiation (IR), and this defect correlated with hypersensitivity to IR. Furthermore, we present evidence that deregulation of Cdc25A occurs predominantly on the post-transcriptional level, as overabundant Cdc25A protein was usually not accompanied by adequate mRNA overexpression. Instead, we demonstrate that aberrantly enhanced protein stability is an important mechanism underlying Cdc25A overabundance in a subset of breast cancer cell lines. Given the frequency of this mechanism, we propose that the DNA integrity checkpoint controlling Cdc25A protein stability might be a common target for deregulation in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14603247     DOI: 10.1038/sj.onc.1206976

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Authors:  Dipankar Ray; Yasuhisa Terao; Dipali Nimbalkar; Li-Hao Chu; Maddalena Donzelli; Tateki Tsutsui; Xianghong Zou; Asish K Ghosh; John Varga; Giulio F Draetta; Hiroaki Kiyokawa
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

2.  SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways.

Authors:  Evgenia Gubanova; Natalia Issaeva; Camilla Gokturk; Tatjana Djureinovic; Thomas Helleday
Journal:  Cell Cycle       Date:  2013-10-04       Impact factor: 4.534

3.  Cdc25A and Dub3 in a high-stakes balancing act.

Authors:  Sebastian D Hayes; J Wade Harper
Journal:  Nat Cell Biol       Date:  2010-04       Impact factor: 28.824

4.  Cdc25 phosphatases: differential regulation by ubiquitin-mediated proteolysis.

Authors:  Lauren M Young; Michele Pagano
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

5.  RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

6.  Identification of differential expressed transcripts in cervical cancer of Mexican patients.

Authors:  Leticia Santos; Ma Fabiola León-Galván; Erika Nahomy Marino-Marmolejo; Ana Paulina Barba de la Rosa; Antonio De León Rodríguez; Roberto González-Amaro; Ramón Gerardo Guevara-González
Journal:  Tumour Biol       Date:  2011-01-13

Review 7.  The role of Cdc25A in the regulation of cell proliferation and apoptosis.

Authors:  Tao Shen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2012-07       Impact factor: 2.505

8.  Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction.

Authors:  Y Honaker; H Piwnica-Worms
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

9.  The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage.

Authors:  Dorthe Helena Larsen; Catherine Poinsignon; Thorkell Gudjonsson; Christoffel Dinant; Mark R Payne; Flurina J Hari; Jannie M Rendtlew Danielsen; Patrice Menard; Jette Christensen Sand; Manuel Stucki; Claudia Lukas; Jiri Bartek; Jens S Andersen; Jiri Lukas
Journal:  J Cell Biol       Date:  2010-08-30       Impact factor: 10.539

10.  GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

Authors:  Tiebang Kang; Yongkun Wei; Yuchi Honaker; Hiroshi Yamaguchi; Ettore Appella; Mien-Chie Hung; Helen Piwnica-Worms
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.